Evaluation of voriconazole pharmacodynamics using time-kill methodology

被引:81
作者
Klepser, ME
Malone, D
Lewis, RE
Ernst, EJ
Pfaller, MA
机构
[1] Univ Iowa, Coll Pharm, Iowa City, IA 52242 USA
[2] Univ Iowa, Coll Med, Iowa City, IA 52242 USA
关键词
D O I
10.1128/AAC.44.7.1917-1920.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Voriconazole is an investigational azole antifungal agent with activity against a variety of fungal species, including fluconazole-susceptible and -resistant Candida species and Cryptococcus neoformans, In this study, we employed in vitro time-kill methods to characterize the relationship between concentrations of voriconazole and its fungistatic activity against Candida albicans, Candida glabrata, Candida tropicalis, and C. neoformans. Isolates were exposed to voriconazole concentrations ranging from 0.0625 to 16 times the MIC, and the viable colony counts were determined over time. The 50 and 90% effective concentrations (EC50 and EC90, respectively) were determined at 8, 12, and 24 h following the addition of voriconazole, At each time point, near-maximal fungistatic activity, as indicated by the EC90, was noted at a drug concentration of approximately three times the MIC. Additionally, EC50 and EC90 did not change over time, thus suggesting that the rate of activity was not improved by increasing concentrations. Voriconazole exhibits non-concentration-dependent pharmacodynamic characteristics in vitro.
引用
收藏
页码:1917 / 1920
页数:4
相关论文
共 11 条
[1]   Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model [J].
Andes, D ;
van Ogtrop, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2116-2120
[2]   Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species [J].
Belanger, P ;
Nast, CC ;
Fratti, R ;
Sanati, H ;
Ghannoum, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (08) :1840-1842
[3]   In vitro activity of voriconazole against Candida species [J].
Kauffman, CA ;
Zarins, LT .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1998, 31 (01) :297-300
[4]   Influence of test conditions on antifungal time-kill curve results: Proposal for standardized methods [J].
Klepser, ME ;
Ernst, EJ ;
Lewis, RE ;
Ernst, ME ;
Pfaller, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) :1207-1212
[5]   Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B against Cryptococcus neoformans [J].
Klepser, ME ;
Wolfe, EJ ;
Pfaller, MA .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (03) :397-401
[6]   Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans [J].
Klepser, ME ;
Wolfe, EJ ;
Jones, RN ;
Nightingale, CH ;
Pfaller, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (06) :1392-1395
[7]   Pharmacodynamics of fluconazole in a murine model of systemic candidiasis [J].
Louie, A ;
Drusano, GL ;
Banerjee, P ;
Liu, QF ;
Liu, WG ;
Kaw, P ;
Shayegani, M ;
Taber, H ;
Miller, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) :1105-1109
[8]   In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. [J].
Marco, F ;
Pfaller, MA ;
Messer, S ;
Jones, RN .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) :161-163
[9]   METHOD FOR RELIABLE DETERMINATION OF MINIMAL LETHAL ANTIBIOTIC CONCENTRATIONS [J].
PEARSON, RD ;
STEIGBIGEL, RT ;
DAVIS, HT ;
CHAPMAN, SW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 18 (05) :699-708
[10]   Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro in vivo correlation data for fluconazole, itraconazole, and Candida infections [J].
Rex, JH ;
Pfaller, MA ;
Galgiani, JN ;
Bartlett, MS ;
EspinelIngroff, A ;
Ghannoum, MA ;
Lancaster, M ;
Odds, FC ;
Rinaldi, MG ;
Walsh, TJ ;
Barry, AL .
CLINICAL INFECTIOUS DISEASES, 1997, 24 (02) :235-247